EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Trapping all ERBB ligands decreases pancreatic lesions in a murine model of pancreatic ductal adenocarcinoma

Kathrin Hedegger, Andreas Blutke, Theresa Hommel, Kerstin E Auer, Nishanth B Nataraj, Moshit Lindzen, Yosef Yarden, Maik Dahlhoff iD

Molecular Oncology · 2023

DOI: 10.1002/1878-0261.13473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Kathrin Hedegger und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Animal Breeding and Biotechnology, Gene Center, LMU München, Germany. Hauptthemen laut MEDLINE: Adenocarcinoma, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest of cancers. Attempts to develop targeted therapies still need to be established. Some oncogenic mechanisms in PDAC carcinogenesis harness the EGFR/ERBB receptor family. To explore the effects on pancreatic lesions, we attempted simultaneous blockade of all ERBB ligands in a PDAC mouse model. To this end, we engineered a molecular decoy, TRAP‐F C , comprising the ligand‐binding domains of both EGFR and ERBB4 and able to trap all ERBB ligands. Next, we generated a transgenic mouse model ( CBA TRAP/0 ) expressing TRAP‐F C ubiquitously under the control of the chicken‐beta‐actin promoter and crossed these mice with KRAS G12D/+ mice ( Kras ) to generate Trap/Kras mice. The resulting mice displayed decreased emergence of spontaneous pancreatic lesion areas and exhibited reduced RAS activity and decreased activities of ERBBs, with the exception of ERBB4, which showed increased activity. To identify the involved receptor(s), we employed CRISPR/Cas9 DNA editing to singly delete each ERBB receptor in the human pancreatic carcinoma cell line Panc‐1. Ablation of each ERBB family member, especially the loss of EGFR or ERBB2/HER2, altered signaling downstream of the other three ERBB receptors and decreased cell proliferation, migration, and tumor growth. We conclude that simultaneously blocking the entire ERBB receptor family is therapeutically more effective than individually inhibiting only one receptor or ligand in terms of reducing pancreatic tumor burden. In summary, trapping all ERBB ligands can reduce pancreatic lesion area and RAS activity in a murine model of pancreatic adenocarcinoma; hence, it might represent a promising approach to treat PDAC in patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAnimalsHumansMiceDisease Models, AnimalLigandsMice, Inbred CBAMice, TransgenicProto-Oncogene Proteins p21(ras)Receptor, ErbB-4ErbB Receptors

Stichwörter der Autor:innen

EGF-family ligandsERBB receptorsKrasPDACPanc-1decoy moleculemouse model

Substanzen

LigandsProto-Oncogene Proteins p21(ras)Receptor, ErbB-4EGFR protein, mouseErbB Receptors

Autor:innen und Institutionen

  • Institute of Molecular Animal Breeding and Biotechnology, Gene Center, LMU München, Germany.
  • Institute of Veterinary Pathology, Center for Clinical Veterinary Medicine, LMU München, Germany.
  • Institute of in vivo and in vitro Models, University of Veterinary Medicine, Vienna, Austria.
  • Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Bugworks Research Inc, CCAMP, Bengaluru, India.

ORCID-Profile: Maik Dahlhoff

Zitieren

APA

Hedegger, K., Blutke, A., Hommel, T., Auer, K. E., Nataraj, N. B., Lindzen, M., Yarden, Y., & Dahlhoff, M. (2023). Trapping all ERBB ligands decreases pancreatic lesions in a murine model of pancreatic ductal adenocarcinoma. Molecular Oncology. https://doi.org/10.1002/1878-0261.13473

Vancouver

Hedegger K, Blutke A, Hommel T, Auer KE, Nataraj NB, Lindzen M, et al. Trapping all ERBB ligands decreases pancreatic lesions in a murine model of pancreatic ductal adenocarcinoma. Molecular Oncology. 2023. doi:10.1002/1878-0261.13473

BibTeX
@article{Hedegger2023,
  author = {Hedegger, Kathrin and Blutke, Andreas and Hommel, Theresa and Auer, Kerstin E and Nataraj, Nishanth B and Lindzen, Moshit and Yarden, Yosef and Dahlhoff, Maik},
  title = {Trapping all ERBB ligands decreases pancreatic lesions in a murine model of pancreatic ductal adenocarcinoma},
  journal = {Molecular Oncology},
  year = {2023},
  doi = {10.1002/1878-0261.13473}
}
Kostenlos starten →